CLINICAL STUDY PROTOCOL AMENDMENT

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects with Cutaneous Neurofibromas

<table>
<thead>
<tr>
<th>Protocol No.</th>
<th>NFX-179-NF1-201</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol/Amendment Date:</td>
<td>20-JUL-2020</td>
</tr>
<tr>
<td>Amendment No.:</td>
<td>1</td>
</tr>
<tr>
<td>Supersedes:</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| Sponsor: | NFlection Therapeutics  
714 Woodcrest Road,  
Wayne, PA 19087  
United States |
| Medical Monitor: | Guy Webster, M.D. Ph.D.  
24-hour telephone: (302) 559-8684  
Email: GWebster@Nflectionrx.com |

CONFIDENTIALITY STATEMENT

This document contains proprietary and confidential information of NFlection Therapeutics. Acceptance of this document constitutes agreement by the recipient that no previously unpublished information contained herein will be published or disclosed without the prior written approval of NFlection Therapeutics with the exception that this document may be disclosed to study staff under your supervision who need to know the contents for conducting the study and to appropriate Institutional Review Boards/Ethics Committees under the condition that the staff have agreed to keep this information confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws, however, NFlection Therapeutics shall be promptly notified of any such disclosure.
INVESTIGATOR COMMITMENT:

I will provide copies of the protocol, any subsequent protocol amendments and access to all information provided by NFlection to the investigational center staff under my supervision. I will discuss this material with them to ensure that they are fully informed about the Investigational Medicinal Product and the study protocol.

I agree to conduct this clinical study according to the attached protocol, except when mutually agreed to with NFlection in writing. I also agree to conduct this study in compliance with all local regulatory requirements, Good Clinical Practices, as well as with the requirements of the appropriate Institutional Review Board(s)/Ethics Committee(s) and any other Institutional requirements.

Printed Name of Investigator

________________________________________

Signature of Investigator

________________________________________

Date
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects with Cutaneous Neurofibromas

<table>
<thead>
<tr>
<th>Protocol No.</th>
<th>NFX-179-NF1-201</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol/Amendment Date:</td>
<td>20-JUL-2020</td>
</tr>
<tr>
<td>Amendment No.:</td>
<td>1</td>
</tr>
<tr>
<td>Sponsor:</td>
<td>NFlection Therapeutics</td>
</tr>
<tr>
<td></td>
<td>714 Woodcrest Road,</td>
</tr>
<tr>
<td></td>
<td>Wayne, PA 19087</td>
</tr>
<tr>
<td></td>
<td>United States</td>
</tr>
</tbody>
</table>

Christopher Powala  
Chief Executive Officer  
NFlection Therapeutics

Guy Webster, M.D., Ph.D.  
Chief Medical Officer  
NFlection Therapeutics

Date: 20-JUL-2020

Date: 07-23-2020

Date: 7/23/2020
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROTOCOL AMENDMENT INVESTIGATOR SIGNATURE PAGE</td>
<td>2</td>
</tr>
<tr>
<td>PROTOCOL Amendment APPROVAL PAGE</td>
<td>3</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>4</td>
</tr>
<tr>
<td>1 AMENDMENT HISTORY</td>
<td>5</td>
</tr>
<tr>
<td>2 AMENDMENT SUMMARY</td>
<td>5</td>
</tr>
<tr>
<td>3 AMENDMENT RATIONALE</td>
<td>5</td>
</tr>
<tr>
<td>4 PROTOCOL CHANGES</td>
<td>6</td>
</tr>
</tbody>
</table>
1 AMENDMENT HISTORY
Protocol footer date: 25-MAY-2020
Previous amendments: None

2 AMENDMENT SUMMARY
The following sections of the NFX-179-NF1-201 protocol with footer date 15-MAY-2020 and with a final NFlection Therapeutics approval signature date of 27-MAY-2020 are amended:

- PROTOCOL APPROVAL PAGE (page 3 of 77)
- Section 4.8 Subject discontinuation from the study
- Section 5.2.3 Visits 3 and 4/Days 8 and 15 (QD treatment)
- Section 5.3 Study cNF tumor identification
- Section 6.2.2 Target cNF ultrasounds
- Section 6.3.1 Demographics.

3 AMENDMENT RATIONALE
These protocol changes are made to:

- Correct a typographic error to the protocol number on the PROTOCOL APPROVAL PAGE
- Respond to recommendations from the Food and Drug Administration; changes to section 4.8
- Correct an error which instructs the investigator to take standardized photographs at Visits 3 and 4; changes to protocol section 5.2.3
- Add the requirement that for each subject Target cNF Tumor number 5 be on the face; changes to protocol section 5.3
- Update the description of the high frequency ultrasound equipment that may be used; changes to section 6.2.2
- Correct a typographic error; changes to section 6.3.1.
4 PROTOCOL CHANGES

PROTOCOL APPROVAL PAGE (page 3 of 77):

Previous protocol number:
NFX-179-NF-201.

Changed protocol number:
NFX-179-NF1-201.

Section 4.8 Subject discontinuation from the study:

Previous paragraph 2:
The investigator may remove a subject from the study if, in the investigator's opinion, it is not in the best interest of the subject to continue the study. Examples of other reasons subjects may be discontinued from the study are a change in compliance with an inclusion or exclusion criterion, occurrence of AEs, occurrence of pregnancy or use of a prohibited therapy. Notification of discontinuation will immediately (within 24 hours) be made to the NFlection study monitor.

Changed paragraph 2:
The investigator will remove a subject from the study if, in the investigator's opinion, it is not in the best interest of the subject to continue the study. The investigator must remove a subject from the study if the subject experiences:

- A Serious Adverse Event the investigator defines as related to the study medication, regardless of the intensity of the event
- A non-serious adverse event the investigator defines as related to study medication that has a severity of severe and requires treatment to resolve.

Examples of other reasons subjects may be discontinued from the study are a change in compliance with an inclusion or exclusion criterion, occurrence of AEs, occurrence of pregnancy or use of a prohibited therapy. Notification of discontinuation will immediately (within 24 hours) be made to the NFlection study monitor.

Section 5.2.3 Visits 3 and 4/Days 8 and 15 (QD treatment):

Previous procedure 7:
Take standardized color photographs of each Target cNF Tumor.

Changed procedure 7:
Procedure 7 is deleted.
Section 5.3 Study cNF tumor identification:
Previous paragraph 3 major bullet 3:
- Face:
  - Vertically from the mandibular ridge to the hairline (for subjects with a receding hair the hairline is defined by a vertical line drawn coronally from tragus to tragus)
  - Horizontally from tragus to tragus, excluding the eyelids and areas within 5mm of the orbital rim.

Changed paragraph 3 major bullet 3:
- Face (Target cNF Tumor #5 must be on the face):
  - Vertically from the mandibular ridge to the hairline (for subjects with a receding hair the hairline is defined by a vertical line drawn coronally from tragus to tragus)
  - Horizontally from tragus to tragus, excluding the eyelids and areas within 5mm of the orbital rim.

Previous paragraph 5 bullet 5:
- Target cNF Tumor #5/green ID stickers

Changed paragraph 5 bullet 5:
- Target cNF Tumor #5/green ID stickers (Target cNF Tumor #5 must be on the face).

Section 6.2.2 Target cNF ultrasounds:
Previous paragraph 2:
The HFUS results will be used to determine the volume of the Target cNF. HFUS imaging will be performed using the Vevo3100-System.

Changed paragraph 2:
The HFUS results will be used to determine the volume of the Target cNF. HFUS imaging will be performed using an appropriate HFUS system (e.g., Vevo3100, GE Logiq E, etc.).

Section 6.3.1 Demographics:
Previous paragraph 1 sentence 3:
In addition, medical and surgical history, EN history, and concomitant illness(es) will be recorded.

Changed paragraph 1 sentence 3:
In addition, medical and surgical history, NF1 history, and concomitant illness(es) will be recorded.